MGTX MeiraGTx Holdings plc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1735438 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,365.9%
TTM net income YoY146.4%
TTM EPS YoY141.2%
Revenue 3-yr CAGR291.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin44.8%
Net margin19.5%
FCF margin-0.7%
EBITDA margin47.8%
Returns
ROE89.7%
ROA26.0%
ROIC (approx.)—
Asset turnover1.34x
Leverage & solvency
Liabilities / assets47.7%
Debt / equity0.00x
Current ratio4.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.02x
Accruals ratio25.6%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $81.39M | $33.28M |
| R&D expense | $129.62M | $119.48M |
| SG&A expense | $52.90M | $54.22M |
| Operating income | -$105.97M | -$164.21M |
| Interest expense | $12.20M | $13.27M |
| Pretax income | -$114.20M | -$147.79M |
| Income tax | $0 | $0 |
| Net income | -$114.20M | -$147.79M |
| EBITDA | -$93.43M | -$151.38M |
| EPS (basic) | -1.42 | -2.12 |
| EPS (diluted) | -1.42 | -2.12 |
| Weighted avg. shares (diluted) | 80.43M | 69.82M |
| Balance sheet | ||
| Cash & equivalents | $65.93M | $105.67M |
| Receivables | $3.00M | $707,000 |
| Inventory | — | $385,000 |
| Current assets | $91.76M | $123.52M |
| PP&E, net | $105.47M | $102.88M |
| Intangibles | $578,000 | $821,000 |
| Total assets | $244.43M | $269.75M |
| Current liabilities | $122.56M | $60.78M |
| Total liabilities | $250.22M | $201.92M |
| Shareholders' equity | -$5.79M | $67.83M |
| Shares outstanding | 81.12M | 78.40M |
| Cash flow statement | ||
| Operating cash flow | -$46.36M | -$104.50M |
| Capital expenditure | $3.83M | $4.96M |
| Free cash flow | -$50.19M | -$109.45M |
| Investing cash flow | -$4.11M | $23.48M |
| Financing cash flow | $12.27M | $54.53M |
| Depreciation & amortization | $12.54M | $12.83M |
| Stock-based compensation | $22.11M | $25.19M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.